Jinling Pharmaceutical Company Limited (SHE:000919)
China · Delayed Price · Currency is CNY 7.77
+0.15 (1.97%)
Feb 4, 2026, 3:04 PM CST
SHE:000919 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,106 | 3,256 | 3,164 | 2,649 | 2,789 | 2,486 |
Other Revenue | 25.02 | 25.02 | 29.52 | 22.15 | 19.62 | 17.82 |
| 3,131 | 3,281 | 3,194 | 2,671 | 2,809 | 2,504 | |
Revenue Growth (YoY) | -13.52% | 2.74% | 19.58% | -4.91% | 12.18% | -1.23% |
Cost of Revenue | 2,530 | 2,676 | 2,557 | 2,142 | 2,181 | 1,942 |
Gross Profit | 601.48 | 605.17 | 637.06 | 528.55 | 628.17 | 561.29 |
Selling, General & Admin | 455.58 | 446.73 | 460.88 | 383.48 | 384.3 | 328.41 |
Research & Development | 121.43 | 110.69 | 79.14 | 74.17 | 57.01 | 43.71 |
Other Operating Expenses | 28.94 | 20.68 | 13 | 18.21 | 19.28 | 15.46 |
Operating Expenses | 607.39 | 579.86 | 556.22 | 477.52 | 458.93 | 387.58 |
Operating Income | -5.91 | 25.31 | 80.84 | 51.03 | 169.24 | 173.71 |
Interest Expense | -4.94 | -2.2 | -1.3 | -0.26 | -0.29 | -0.38 |
Interest & Investment Income | 72.76 | 63.91 | 58.14 | 34.98 | 46.4 | 49.29 |
Currency Exchange Gain (Loss) | 0.04 | 0.04 | 0.02 | 0.08 | -0 | 0 |
Other Non Operating Income (Expenses) | 0.89 | -0.16 | -1.07 | -1.45 | -1.42 | -1.09 |
EBT Excluding Unusual Items | 62.82 | 86.9 | 136.63 | 84.38 | 213.92 | 221.53 |
Impairment of Goodwill | -86.3 | -86.3 | - | - | -45.97 | -45.59 |
Gain (Loss) on Sale of Investments | 5.78 | 14.39 | -0.96 | -27.14 | -29.95 | -49.81 |
Gain (Loss) on Sale of Assets | 16.86 | 17.03 | -0.7 | 61.83 | 51.98 | 0.17 |
Asset Writedown | -0.02 | -5.7 | - | - | -1.56 | -5.54 |
Other Unusual Items | 20.27 | 13.69 | 13.4 | 8.71 | 6.38 | 4.37 |
Pretax Income | 19.42 | 40.01 | 148.36 | 127.77 | 194.81 | 125.13 |
Income Tax Expense | 12.23 | 22.05 | 19.6 | 13.9 | 41.88 | 31.47 |
Earnings From Continuing Operations | 7.18 | 17.95 | 128.76 | 113.87 | 152.94 | 93.66 |
Minority Interest in Earnings | 24.93 | 22.46 | -22.57 | -8.58 | -32.31 | -28.52 |
Net Income | 32.11 | 40.41 | 106.19 | 105.28 | 120.63 | 65.14 |
Net Income to Common | 32.11 | 40.41 | 106.19 | 105.28 | 120.63 | 65.14 |
Net Income Growth | -62.37% | -61.95% | 0.87% | -12.72% | 85.19% | -55.18% |
Shares Outstanding (Basic) | 619 | 593 | 504 | 504 | 504 | 504 |
Shares Outstanding (Diluted) | 619 | 593 | 504 | 504 | 504 | 504 |
Shares Change (YoY) | 9.53% | 17.56% | 0.01% | -0.02% | -0.01% | 0.02% |
EPS (Basic) | 0.05 | 0.07 | 0.21 | 0.21 | 0.24 | 0.13 |
EPS (Diluted) | 0.05 | 0.07 | 0.21 | 0.21 | 0.24 | 0.13 |
EPS Growth | -65.65% | -67.63% | 0.86% | -12.70% | 85.22% | -55.19% |
Free Cash Flow | 168.78 | -47.44 | -25.85 | -49.05 | 129.26 | 20.06 |
Free Cash Flow Per Share | 0.27 | -0.08 | -0.05 | -0.10 | 0.26 | 0.04 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 |
Dividend Growth | - | - | - | - | - | -41.18% |
Gross Margin | 19.21% | 18.44% | 19.95% | 19.79% | 22.36% | 22.42% |
Operating Margin | -0.19% | 0.77% | 2.53% | 1.91% | 6.02% | 6.94% |
Profit Margin | 1.03% | 1.23% | 3.33% | 3.94% | 4.29% | 2.60% |
Free Cash Flow Margin | 5.39% | -1.45% | -0.81% | -1.84% | 4.60% | 0.80% |
EBITDA | 134.33 | 169.3 | 229.81 | 173.57 | 291.14 | 293.59 |
EBITDA Margin | 4.29% | 5.16% | 7.20% | 6.50% | 10.37% | 11.73% |
D&A For EBITDA | 140.24 | 143.99 | 148.97 | 122.54 | 121.9 | 119.88 |
EBIT | -5.91 | 25.31 | 80.84 | 51.03 | 169.24 | 173.71 |
EBIT Margin | -0.19% | 0.77% | 2.53% | 1.91% | 6.02% | 6.94% |
Effective Tax Rate | 63.00% | 55.12% | 13.21% | 10.88% | 21.50% | 25.15% |
Revenue as Reported | 3,131 | 3,281 | 3,194 | 2,671 | 2,809 | 2,504 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.